Related Experiment Video
Updated: Aug 7, 2025

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Effect of ticagrelor on the function of tunneled cuffed catheter in maintenance hemodialysis patients
Jianming Shen1, Yanyan Deng1, Liping Wang1
1Department of Nephrology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
Insights
Ticagrelor did not extend the functional lifespan of tunneled cuffed catheters (TCC) in maintenance hemodialysis (MHD) patients compared to aspirin. The study found TCCs lasted longer in the aspirin group, suggesting ticagrelor may not be optimal for this indication.
Area of Science:
- Nephrology
- Vascular Access
- Pharmacology
Background:
- Tunneled cuffed catheters (TCC) are crucial for vascular access in maintenance hemodialysis (MHD).
- Catheter dysfunction, often due to thrombosis, limits TCC lifespan and impacts patient treatment.
- Antiplatelet therapy is used to maintain catheter patency, but optimal drug choice requires investigation.
Purpose of the Study:
- To evaluate the efficacy of ticagrelor compared to aspirin in maintaining TCC function and longevity in MHD patients.
- To assess the impact of ticagrelor on catheter dysfunction, coagulation, and adverse events.
Main Methods:
- A prospective study enrolled 80 MHD patients with TCCs, divided into a control group (aspirin) and an observation group (ticagrelor).
- Data collected included catheter lifespan, dysfunction rates, coagulation parameters, and adverse events over the study period.
- Statistical analysis, including log rank test, was used to compare outcomes between the groups.
Main Results:
- The median TCC lifespan was significantly longer in the control group (aspirin) compared to the observation group (ticagrelor).
- Log rank test confirmed a statistically significant difference (p < 0.001) in catheter survival between the groups.
- While ticagrelor was associated with reduced catheter dysfunction, this did not translate to a longer overall catheter lifespan in this study.
Conclusions:
- Ticagrelor may reduce TCC dysfunction by preventing thrombosis, but it did not prolong catheter lifespan compared to aspirin in MHD patients.
- Further research is needed to optimize antiplatelet strategies for TCCs in MHD to balance patency and longevity.
- The findings suggest that ticagrelor might not be the preferred agent for maintaining TCC function in MHD patients, despite potential benefits in reducing dysfunction.
Objective:
To observe the effect of ticagrelor on the function of a tunneled cuffed catheter (TCC) in maintenance hemodialysis (MHD) patients.
Methods:
Eighty MHD patients (control group: 39 cases, observation group: 41 cases) using TCC as vascular access were enrolled from January 2019 to October 2020 in this prospective study. Patients in the control group were routinely treated with aspirin for antiplatelet therapy, while patients in the observation group were treated with ticagrelor. The catheter life time, catheter dysfunction, coagulation function, and antiplatelet drug-related adverse events of the two groups were recorded.
Results:
The median life time of TCC in the control group was significantly higher than that in the observation group. Moreover, the log rank test showed that the difference was statistically significant (p < 0.001).
Conclusion:
Ticagrelor may reduce the incidence of catheter dysfunction and prolong the life time of the catheter by preventing and reducing the thrombosis of TCC in MHD patients, without obvious side effects.
More Related Videos
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Continuous Renal Replacement Therapy
Cardiac Catheterization IV: Nursing Management
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management

